Welcome to Tymora Analytical Operations!

Tymora Analytical Operations provides new research services, products, and reagents to the life science R&D organizations. Tymora has developed nanoscale platform technologies – with PolyMAC and pIMAGO as the lead products – for unmet needs in analysis of protein phosphorylation that relates to the onset of numerous diseases, most notably cancer.

Welcome to Tymora Analytical Operations!

Tymora Analytical Operations provides new research services, products, and reagents to the life science R&D organizations. Tymora has developed nanoscale platform technologies – with PolyMAC and pIMAGO as the lead products – for unmet needs in analysis of protein phosphorylation that relates to the onset of numerous diseases, most notably cancer.

Proteomics Services

Our recently published manuscript in PNAS demonstrates the feasibility of identifying phosphoproteins in plasma-derived vesicles. Our goal is to help doctors and scientists provide earlier diagnoses and more effective treatments for cancer and other abnormalities.

 

Learn more

Products

Detection of protein phosphorylation is essential in understanding an organism’s signaling pathways and preventing and treating cancer and other abnormalities. This is why we offer PolyMAC and pIMAGO, effective R&D products for phosphorylation analysis.

 

Learn more

Collaborate

Contact us for more information or to discuss opportunities available.

 

Learn more
Contact us

pIMAGO

Universal non-antibody detection of phosphoproteins.
Available formats include:
Western Blot, Microplate, & Microarray

One-Step PolyMAC

The binding of phosphopeptides and a covalent capture occur in a single step with Tymora’s PolyMAC product. Utilize PolyMAC for effective phosphopeptide enrichment.

Interested in collaboration?

Contact us for more information or to discuss opportunities available.

Tymora News

Tymora receives $225,000 grant to advance prostate cancer research

Federal funding will help a Purdue-affiliated company research technology that could lead to a new way to distinguish aggressive forms of prostate cancer from indolent forms of the disease.

Read more

Tymora awarded NIH Phase II grant to advance protein phosphorylation tech

NEW YORK (GenomeWeb) – Startup Tymora Analytical Operations this month was awarded a Phase II SBIR grant from the National Institutes of Health to develop multiplexed and reverse-phase array versions of its pImago system for…

Read more

Tymora receives $640K NIH Phase I for new biomarker discovery technology

A two-year grant from the National Institutes of Health will fund work by a Purdue Research Park-based company to improve methods to screen blood plasma samples for biomarkers, which are measurable indicators of a disease, to expedite diagnosis and treatment…

Read more

Recent publication by Tymora Analytical featured on the cover of ChemBioChem

Our paper, “Multiplexed Imaging of Protein Phosphorylation on Membranes Based on Ti(IV) Functionalized Nanopolymers,” was recently featured as the cover of ChemBioChem for their current issue published on May 17, 2016, Volume 17 Issue 10.

Read more

Tymora Analytical creates new line of products for cancer research

Cancer researchers in educational and commercial settings have two new tools from a Purdue Research Park-based company to help them with target detection and discovery of novel drugs to fight the disease…

Read more

Tymora receives $500,000 NSF Phase II grant for drug-development technology

The National Science Foundation has awarded a Phase II Small Business Innovation Research (SBIR) grant to a life sciences company to develop a technology called pIMAGO that promotes the discovery of new disease targets in laboratory…

Read more